medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in brain malignant tumors

Yutong Wu[1,2,3#], Chen Sun[1,2,4#], Zhenjian Ge[1,2,3#], Huimei Zhou[1,2,4], Xutai Li[1,2,4#], Wenkang Chen[1,2,3], Yingqi Li[1,2,5], Shengjie Lin[1,2,3], Pengwu Zhang[1,2], Wuping Wang[1,2,5], Siwei Chen[1,2,5], Wei Li[6], Jun Hu[7*], Ling Ji[8*], Yongqing Lai[1,2*]

1 Department of Urology, Peking University Shenzhen Hospital, Shenzhen, 518036; 2Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036; 3 Shantou University Medical College, Shantou, Guangdong 515041; 4 The Fifth Clinical Medical College of Anhui Medical University, Hefei 230032; 5 Shenzhen University Health Science Center, Shenzhen, China 518055; 6 Shenzhen KeRuiDa Health Technology Co. , Ltd. , Shenzhen, 518071; 7 Department of Neurology, Peking University Shenzhen Hospital, Shenzhen, 518036; 8 Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036.

# Contributed equally to this work.

*Corresponding author: Yongqing Lai, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: yqlord@163. com; Ling Ji, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 1120303921@qq.com; Jun Hu, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: dochj@163.com.

Background: Brain malignant tumors is a serious threat to human health and causes heavy economic burden. Enhanced MRI is widely used in the diagnosis of brain tumors. However, false-positive results of enhanced MRI will bring unnecessary mental pain, expensive examination costs, physical injuries, and other adverse consequences; while false-negative results of enhanced MRI bring delayed treatment, and patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival period. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-negative and false-positive rates of brain-enhanced MRI. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in brain malignant tumors.

Patients and methods: 235 subjects (malignant group, n=75; benign group, n=160) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D.

Results: The sensitivity of YiDiXie™-SS in enhanced MRI-positive patients was 98.4% (95% CI: 91.3% - 99.9%; 60/61) and its specificity was 62.5% (95% CI: 38.6% - 81.5%; 10/16). This means that the application of YiDiXie™-SS reduces the false-positive rate of brain enhanced MRI by 62.5% (95% CI: 38.6% - 81.5%; 10/16) with essentially no increase in malignancy leakage. The sensitivity of YiDiXie™-HS in enhanced MRI-negative patients was 85.7% (95% CI: 60.1% - 97.5%; 12/14) and its specificity was 84.7% (95% CI: 78.0% - 89.7%; 122/144). This means that the application of YiDiXie™-HS reduces the false-negative rate of brain-enhanced MRI by 85.7% (95% CI: 60.1% - 97.5%; 12/14). The sensitivity of YiDiXie™-D in enhanced MRI-positive patients was 34.4% (95% CI: 23.7% - 47.0%; 21/61) and its specificity was 93.8% (95% CI: 71.7% - 99.7%; 15/16). This means that the application of YiDiXie™-HS reduces the false-positive rate of brain-enhanced MRI by 93.8% (95% CI: 71.7% - 99.7%; 15/16).

Conclusion: YiDiXie™-SS significantly reduces the false-positive rate of brain-enhanced MRI without increasing the delay in treatment of malignant tumors. YiDiXie™-HS dramatically reduces the false-negative rate of brain-enhanced MRI. YiDiXie™-D dramatically reduces the false-positive rate of brain-enhanced MRI. The YiDiXie™ test has significant diagnostic value in brain tumors, and is expected to solve the problems of "high false-negative rate of enhanced MRI" and "high false-positive rate of enhanced MRI" in brain tumors.

Clinical trial number: ChiCTR2200066840.

Key words: Brain tumor, Enhanced MRI, False-positive, False-negative, YiDiXie™-SS, YiDiXie™-HS, YiDiXie™-D

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

INTRODUCTION

Brain malignant tumors is one of the common malignant tumors. According to the latest data, in 2022, there will be 321,476 new cases of brain malignant tumors in the world, and there will be 248,305 new deaths, accounting for 2.6% of the total number of deaths of malignant tumors in the world and ranking 12th[1]; Compared to 2020, the mortality rate of brain malignant tumors increased by 0.1% in 2022 and is still trending upward each year[2]. Gliomas are the most common primary intracranial tumors, accounting for approximately 80-85% of all malignant brain tumors[3]. Treatment of gliomas requires an integrated multidisciplinary approach that includes surgical resection, radiotherapy, systemic therapy, and supportive care, and surgery to maximize the safe removal of the tumor is the first-line treatment for gliomas[4]. High-grade gliomas are characterized by high aggressiveness, high disability, and high recurrence rates, with a median survival of less than two years[5-6] and a 5-year survival rate of less than 10%. Early diagnosis not only improves survival outcomes and optimizes survival by treating early in the curable low-grade stage, but also reduces the heavy burden of treatment and the cost of treatment for families and society[7]. Therefore, brain malignant tumors are not only a serious threat to human health, but also a heavy burden to the patient, family, and society.

Enhanced MRI is widely used in the diagnosis of brain tumors. On the one hand, enhanced MRI can produce a large number of false-positive results. When enhanced MRI is positive, patients are usually treated with surgery or invasive therapy. False-positive enhanced MRI results mean that benign diseases are misdiagnosed as malignant tumors, and patients may have to bear the negative consequences of unnecessary mental pain, expensive surgery and examination costs, surgical trauma, and even loss of function. Therefore, there is an urgent need to find a convenient, cost-effective and noninvasive diagnostic method to reduce the false-positive rate of brain-enhanced MRI.

On the other hand, enhanced MRI can produce a large number of false-negative results. When enhanced MRI is negative, patients usually take observation and regular follow-up. Enhanced MRI false-negative results mean that malignant tumors are misdiagnosed as benign diseases, which will likely lead to delayed treatment, progression of malignant tumors, and may even develop into advanced stages. Patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival. Therefore, there is an urgent need to find a convenient, economical and noninvasive diagnostic method to reduce the false-negative rate of brain-enhanced MRI.

Based on the detection of novel tumor markers of miRNA in serum, Shenzhen KeRuiDa Health Technology Co., Ltd. has developed an in vitro diagnostic test, YiDiXie ™ all-cancer test (hereinafter referred to as YiDiXie™ test), which can detect multiple types of cancers with only 200 microliters of whole blood or 100 microliters of serum each time[8]. The YiDiXie ™ test consists of three different tests, YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D[8].

The purpose of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in brain malignant tumors.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

PATIENTS AND METHODS

Study design

The present work is part of the sub-study "Evaluation of the YiDiXie™ test for adjuvant diagnostic value in multiple tumors" of the SZ-PILOT study (ChiMRIR2200066840).

The SZ-PILOT study (ChiMRIR2200066840) is a single-center, prospective, observational study. Participants signing a general informed consent for donation of remaining samples at the time of admission or physical examination were enrolled, and their remaining serum samples of 0.5 ml were collected for this study.

The present study was blinded. Neither the laboratory personnel performing the YiDiXie™ test nor the KeRuiDa laboratory technicians evaluating the results of the YiDiXie™ test were aware of the participants' clinical information. The clinical experts assessing the subjects' clinical information were also unaware of the results of the YiDiXie™ test.

The present study was approved by the Ethics Committee of Shenzhen Hospital of Peking University and was conducted in accordance with the International Conference on Harmonization (ICH) Code of Practice for the Quality Management of Pharmaceutical Clinical Trials and the Declaration of Helsinki.

Participants

Two groups of subjects were enrolled separately, and the subjects meeting the inclusion criteria were all consecutively included.

Initially, this study included hospitalized patients with "suspected (solid or hematological) malignancy" who signed a general informed consent form for donation of the remaining samples. Participants with a postoperative pathology diagnosis of "malignant tumor" were included in the malignant tumor group, and those with a postoperative pathology diagnosis of "benign tumor" were included in the benign tumor group. Subjects with ambiguous pathological findings were excluded from the present study. Some of the samples from the malignant tumor group were used in our previous article[8].

Subjects failing the serum sample quality test prior to the YiDiXie™ test were excluded from the present study. For details of enrollment and exclusion, please refer to in our previous article[8].

Sample collection, processing

The serum samples used in the present study were taken from serum left over after a normal clinic visit, no additional blood draws were required. About 0.5 ml of serum samples were collected from the remaining serum of subjects in the Medical Laboratory and kept at -80°C for the subsequent use in the YiDiXie™ test.

The YiDiXie test

The YiDiXie™ test was accomplished with YiDiXie™ all-cancer detection kit, an in-vitro diagnostic kit developed and produced by Shenzhen KeRuiDa Health Technology Co..[8] It determines the presence of cancer in a subject's body by detecting the expression levels of dozens of miRNA biomarkers in the serum.[8] Appropriate thresholds are predefined for each miRNA biomarker to ensure that high specificity is achieved for each miRNA marker, and these independent assays are integrated in a concurrent assay format to dramatically increase the sensitivity and maintain the high specificity for broad-spectrum cancers.[8]

The YiDiXie™ test consists of three differently characterized tests: YiDiXie™-HS, YiDiXie™-SS, and YiDiXie™-D.[8] YiDiXie™-HS (YiDiXie™-Highly Sensitive, YiDiXie™-HS) has been developed with a balance of sensitivity and specificity.[8] YiDiXie™-HS (YiDiXie™-Highly Sensitive, YiDiXie™-HS) was developed with a balance of sensitivity and specificity.[8] YiDiXie™-SS (YiDiXie™-Super Sensitive,

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

YiDiXie™-SS) dramatically increased the number of miRNA assays in order to achieve extremely high sensitivity for all clinical stages of all malignant tumor types.[8] YiDiXie ™ -D (YiDiXie ™ -Diagnosis, YiDiXie ™ -D) significantly raises the diagnostic threshold of individual miRNA tests to achieve very high specificity for the whole spectrum of malignant tumor types.[8]

According to the instructions of the YiDiXie™ all-cancer detection kit, the YiDiXie ™ test was performed. refer to in our previous article[8] for the detailed procedure.

The raw test results were evaluated by the laboratory technicians of Shenzhen KeRuiDa Health Technology Co., Ltd. and the outcome of the YiDiXie ™ test was determined to be either "positive" or "negative".[8]

Diagnosis of enhanced MRI

The diagnostic conclusion of the enhanced MRI is considered "positive" or "negative". A positive result is determined if the diagnostic conclusion is positive, more positive, or favors a malignant tumor. Negative results are determined if the diagnosis is positive, more positive or favors a benign tumor, or if the diagnosis is ambiguous as to whether the tumor is benign or malignant.

Extraction of clinical data

Clinical, pathological, laboratory, and imaging data in this study were extracted from the subjects' hospitalized medical records or physical examination reports. For clinical staging, assessment was done by trained clinicians according to the AJCC staging manual (7th or 8th edition)[9-10].

Statistical analyses

Descriptive statistics were reported for demographic and baseline characteristics. The number and percentage of subjects in each category were calculated for categorical variables; for continuous variables, the total number of subjects (n), mean, standard deviation (SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), and minimum and maximum values were calculated. Wilson (score) method was used to calculate 95% confidence intervals (CI) for multiple indicators.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

RESULTS

Participant disposition

235 subjects (malignant group, n=75; benign group, n=160) were finally included in this study. The demographic and clinical characteristics of the 235 study subjects are presented in Table 1.

The two groups of study subjects were comparable in terms of demographic and clinical characteristics (Table 1). The mean (standard deviation) age was 46.0(13.71) years and 41.7%(98/235) were female.

Table 1. Participants' demographic and clinical manifestation

	Malignant (n = 75)		Benign (n = 160)		Total (N = 235)	
Age, years						
Mean (SD)	44.0	(15.33)	47.0	(12.82)	46.0	(13.71)
Median (Q1,Q3)	41	(32, 56)	47	(37, 56)	46	(36, 56)
Min, max	6,	79	11,	75	6,	79
Age, group, n (%)						
< 50	49	(65.3)	92	(57.5)	141	(60.0)
⩾ 50	26	(34.7)	68	(42.5)	94	(40.0)
< 65	65	(86.7)	145	(90.6)	210	(89.4)
⩾ 65	10	(13.3)	15	(9.4)	25	(10.6)
Sex, n (%)						
Female	39	(52.0)	59	(36.9)	98	(41.7)
Male	36	(48.0)	101	(63.1)	137	(58.3)
Body mass index (kg/m2)						
n	55		120		175	
Mean (SD)	23.4	(3.57)	23.8	(3.45)	23.7	(3.48)
Median (Q1,Q3)	23.4	(21.3, 25.7)	23.5	(21.9, 25.8)	23.5	(21.6, 25.8)
Min, max	15.7	31.3	15.6	38.3	15.6	38.3
Body mass index category, n (%)						
Underweight	5	(6.7)	4	(2.5)	9	(3.8)
Benign	29	(38.7)	65	(40.6)	94	(40.0)
Overweight	14	(18.7)	42	(26.3)	56	(23.8)
Obese	7	(9.3)	9	(5.6)	16	(6.0)
Missing	20	(26.7)	40	(25.0)	60	(25.5)

Q1,Q3, first quartile, third quartile; SD, standard deviation.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Diagnostic performance of enhanced MRI

As shown in Table 2, the sensitivity of enhanced MRI was 81.3% (95% CI: 71.1% - 88.5%; 61/75) and its specificity was 90.0% (95% CI: 84.4% - 93.8%; 144/160).

Table 2. The performance of enhanced MRI

	Malignant	Benign	Total
	75	160	235
Positive	61	16	77
Negative	14	144	158
SEN = 61/75 = 81.3% (71.1% - 88.5%)		SPE = 144/160 = 90.0% (84.4% - 93.8%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic Performance of YiDiXie™-SS in enhanced MRI-positive patients

To address the challenge of high false-positive rate of brain enhanced MRI, YiDiXie ™ -SS was applied to enhanced MRI-positive patients.

As shown in Table 3, the sensitivity of YiDiXie™ -SS in enhanced MRI-positive patients was 98.4% (95% CI: 91.3% - 99.9%; 60/61) and its specificity was 62.5% (95% CI: 38.6% - 81.5%; 10/16).

This means that the application of YiDiXie™-SS reduces the false-positive rate of brain enhanced MRI by 62.5% (95% CI: 38.6% - 81.5%; 10/16) with essentially no increase in malignancy leakage.

Table 3. The performance of YiDiXie™-SS in enhanced MRI-positive patients

	Malignant	Benign	Total
	61	16	77
Positive	60	6	66
Negative	1	10	11
SEN = 60/61 = 98.4% (91.3% - 99.9%)		SPE = 10/16 = 62.5% (38.6% - 81.5%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Diagnostic Performance of YiDiXie™-HS in enhanced MRI-negative patients

To address the challenge of high false-negative rate of brain enhanced MRI, YiDiXie ™ -HS was applied to enhanced MRI-negative patients.

As shown in Table 4, the sensitivity of YiDiXie™ -HS in enhanced MRI-negative patients was 85.7% (95% CI: 60.1% - 97.5%; 12/14) and its specificity was 84.7% (95% CI: 78.0% - 89.7%; 122/144).

This means that the application of YiDiXie ™ -HS reduces the false-negative rate of brain enhanced MRI by 85.7% (95% CI: 60.1% - 97.5%; 12/14).

Table 4. The performance of YiDiXie™-HS in enhanced MRI-negative patients

	Malignant	Benign	Total
	14	144	158
Positive	12	22	34
Negative	2	122	124
SEN = 12/14 = 85.7% (60.1% - 97.5%)		SPE = 122/144 = 84.7% (78.0% - 89.7%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of YiDiXie™-D in enhanced MRI-positive patients

The false-positive consequences of certain brain tumors are significantly more severe than the false-negative consequences, so YiDiXie ™ -D was applied to such patients to reduce their false-positive rates.

As shown in Table 5, YiDiXie ™ -D had a sensitivity of 34.4% (95% CI: 23.7% - 47.0%; 21/61) and its specificity was 93.8% (95% CI: 71.7% - 99.7%; 15/16) in patients with positive enhanced MRI.

This means that YiDiXie™-SS reduces the false positive rate of enhanced MRI by 93.8% (95% CI: 71.7% - 99.7%; 15/16).

Table 5. The performance of YiDiXie™-D in enhanced MRI-positive patients

	Malignant	Benign	Total
	61	16	77
Positive	21	1	22
Negative	40	15	55
SEN = 21/61 = 34.4% (23.7% - 47.0%)		SPE = 15/16 = 93.8% (71.7% - 99.7%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

DISCUSSION

Clinical significance of YiDiXie™-SS in enhanced MRI-positive patients

For patients with positive brain-enhanced MRI, both the sensitivity and specificity of further diagnostic approaches are important. A higher false-negative rate means that more malignant tumors are underdiagnosed, which will lead to a delay in their treatment, progression of the malignant tumor, and possibly even development of advanced stages. Higher false-positive rates mean more benign tumors are misdiagnosed and will likely lead to unnecessary surgery or invasive treatment.

Weighing both the sensitivity and specificity is essentially a trade-off between the "harm of malignant tumors missed" and the "harm of benign diseases misdiagnosed". Generally speaking, the misdiagnosis of benign brain tumors as malignant tumors will usually lead to unnecessary surgery or invasive treatment, without affecting the patient's prognosis, and the cost of treatment is much lower than that of advanced cancer. Thus, the risk of underdiagnosis of malignant tumors in the brain due to false negatives is much greater than the risk of misdiagnosis of benign diseases due to false positives. Furthermore, the positive predictive value was higher in patients with positive brain enhancement MRI. Even if the false-negative rate is comparable to the false-positive rate, the harm is greater. Thus, YiDiXie™-SS, which has very high sensitivity but slightly lower specificity, was chosen to reduce the false-positive rate of MRI scans of brain tumors.

As shown in Table 3, YiDiXie™-SS had a sensitivity of 98.4% (95% CI: 91.3% - 99.9%; 60/61) and its specificity was 62.5% (95% CI: 38.6% - 81.5%; 10/16) in patients with positive enhanced MRI. The above results suggest that YiDiXie™-SS reduces the false-positive rate of brain-enhanced MRI by 62.5% (95% CI: 38.6% - 81.5%; 10/16) while maintaining a sensitivity close to 100%.

Shortly, YiDiXie™-SS substantially reduces the risk of misdiagnosis of benign tumors in patients with false-positive brain-enhanced MRI with essentially no increase in delayed treatment of malignant tumors. Consequently, YiDiXie™-SS satisfies the clinical needs well and possesses important clinical significance and a wide range of application prospects.

Clinical significance of YiDiXie™-HS in enhanced MRI-negative patients

For patients with negative enhancement MRI, further diagnostic methods of both the sensitivity and specificity are important. A higher false-negative rate means that more malignant tumors are missed, which will lead to a delay in their treatment, progression of malignant tumors, and possibly even development of advanced stages. Consequently, the patients will have to bear the adverse consequences of poor prognosis, short survival, poor quality of life, and high cost of treatment. A higher false-positive rate means more benign tumors are misdiagnosed, which will likely lead to unnecessary surgery or invasive treatment.

Weighing both the sensitivity and specificity is essentially a trade-off between the "danger of malignant tumors being missed" and the "danger of benign tumors being misdiagnosed". Generally speaking, misdiagnosis of benign brain tumors as malignant tumors will usually lead to unnecessary surgery or invasive treatment, which will not affect the patient's prognosis, and the cost of treatment is much lower than that of advanced cancers. Thus, a higher false-negative rate results in a greater risk of "underdiagnosis of malignant tumors" in the brain. In addition, the negative predictive value is higher in patients with negative brain enhanced MRI. The higher false-positive rate results in a greater risk of misdiagnosis of benign diseases. Thus, the highly sensitive and specific YiDiXie™-HS was chosen to reduce the false negative rate of brain enhanced MRI.

As shown in Table 4, YiDiXie™-HS had a

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

sensitivity of 85.7% (95% CI: 60.1% - 97.5%; 12/14) and a specificity of 84.7% (95% CI: 78.0% - 89.7%; 122/144) in patients with negative enhanced MRI. The above results suggest that the application of YiDiXie™-HS reduced the false-negative rate of enhanced MRI by 85.7% (95% CI: 60.1% - 97.5%; 12/14).

Briefly, YiDiXie™-HS significantly reduces the risk of malignant tumor underdiagnosis in patients with false-negative brain-enhanced MRI. Consequently, YiDiXie™-HS fulfills the clinical needs well, and is of great clinical significance and broad application prospects.

Diagnostic performance of YiDiXie™-D in enhanced MRI-positive patients

Enhanced MRI positive patients usually undergo surgery or invasive treatment. Nevertheless, in some cases, the choice of surgery or invasive treatment needs to be made with extra caution, and therefore further diagnosis is required, e.g., smaller tumors, tumors involving important functional areas of the brain, patients in poor general condition, etc..

Both the sensitivity and specificity of further diagnostic methods are important in patients with positive brain-enhanced MRI. Trading off both the sensitivity and specificity is essentially a trade-off between the "danger of underdiagnosis of malignant tumors" and the "danger of misdiagnosis of benign tumors". As smaller tumors have a lower risk of tumor progression and distant metastasis, the risk of underdiagnosis of malignant tumors due to false negatives is much lower than the risk of misdiagnosis of benign tumors due to false positives. In tumors that involve important functional areas of the brain, because surgery or invasive treatment may damage important brain functions, the risk of misdiagnosis of benign tumors due to false positives is much higher than the risk of misdiagnosis of malignant tumors due to false negatives. In patients with poor general conditions, the perioperative risk is much higher than the general condition, and therefore the risk of misdiagnosis of benign tumors due to false positives is much higher than the risk of malignant tumors due to false negatives. Thus, YiDiXie™-D, which is highly specific but less sensitive, was chosen to reduce the false-positive rate of brain-enhanced MRI in these patients.

As shown in Table 5, YiDiXie™-D had a sensitivity of 34.4% (95% CI: 23.7% - 47.0%; 21/61) and its specificity was 93.8% (95% CI: 71.7% - 99.7%; 15/16) in patients with positive enhanced MRI. The above results suggest that YiDiXie™-SS reduced the false-positive rate of enhanced MRI by 93.8% (95% CI: 71.7% - 99.7%; 15/16).

In brief, YiDiXie™-D dramatically reduces the risk of unnecessary surgery or serious perioperative complications in these patients. As such, YiDiXie™-D well meets the clinical needs and possesses important clinical significance and a wide range of application prospects.

The YiDiXie™ test are expected to solve 2 challenges in brain tumors

First, YiDiXie™-SS can reduce the risk of misdiagnosis of benign brain tumors as malignant tumors. On the one hand, YiDiXie™-SS drastically reduces the risk of misdiagnosis of benign brain tumors with surgery or invasive treatment. Patients with positive brain enhancement MRIs usually undergo surgery or invasive treatment. Because of the high rate of false-positive enhanced MRIs, a large number of patients with benign brain tumors are subjected to unnecessary surgery or invasive treatment. As shown in Table 3, YiDiXie™-SS reduces the false-positive rate of enhanced MRI of the brain by 62.5% (95% CI: 38.6% - 81.5%; 10/16) with essentially no increase in malignant tumor leakage. Therefore, YiDiXie™-SS substantially reduces the risk of incorrect surgery or invasive treatment in patients with benign brain tumors without increasing malignant tumor delay in treatment.

On the other hand, YiDiXie™-SS considerably

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

reduces the stress of non-essential work for clinicians. When a brain enhanced MRI is positive, surgery or invasive treatment is usually performed on that patient. Their timely completion is directly dependent on the number of clinicians. In many parts of the world, months or even more than a year's worth of appointments are available. Inevitably, this delays the treatment of malignant cases among them, thus it is not uncommon for patients with enhanced MRI-positive brain tumors awaiting surgical or invasive treatment to develop malignant progression or even distant metastases. As shown in Table 3, YiDiXie ™ -SS reduces the false-positive rate of brain-enhanced MRI by 62.5% (95% CI: 38.6% - 81.5%; 10/16) with essentially no increase in malignant tumor leakage. Accordingly, YiDiXie ™ -SS significantly relieves clinicians of non-essential workload and promotes timely diagnosis and treatment of malignant tumors or other diseases of the brain that would otherwise be delayed in treatment.

Second, YiDiXie™-HS greatly reduces the risk of underdiagnosis of malignant tumors of the brain. When an enhanced MRI is negative, it usually rules out the possibility of a brain malignancy for the time being. The higher rate of false-negative enhanced MRI results in delayed treatment for a large number of patients with brain malignant tumors. As shown in Table 4, YiDiXie™-HS reduced the false negative rate of enhanced MRI by 85.7% (95% CI: 60.1% - 97.5%; 12/14). Therefore, YiDiXie™ -HS substantially reduces the probability of false-negative enhanced MRI miss-diagnosis of malignant tumors and facilitates timely diagnosis and treatment of patients with malignant tumors of the brain who would otherwise be delayed in treatment.

Third, YiDiXie ™ -D decreases the risk of misdiagnosis of benign brain tumors followed by wrong surgery or serious perioperative complications. When the enhanced MRI is positive, the patient usually undergoes surgery or invasive treatment. In cases such as small tumors, tumors accumulating in important functional areas of the brain, and patients in poor general condition, surgery or invasive treatment may result in unnecessary surgical trauma or serious perioperative complications. Thus these patients require extra caution before surgery or invasive treatment. As shown in Table 5, YiDiXie ™ -SS reduced the false-positive rate of enhanced MRI by 93.8% (95% CI: 71.7% - 99.7%; 15/16). As a result, YiDiXie™-D substantially reduced the risk of wrong surgery or serious perioperative complications in these patients.

Final, The YiDiXie™ test enables "just-in-time" diagnosis of brain tumors. On the one hand, the YiDiXie™ test only requires microscopic amounts of blood, enabling patients to complete the diagnostic process non-invasively without having to leave their homes. A single the YiDiXie™ test requires only 20 microliters of serum, which is approximately the same amount as 1 drop of whole blood[8]. Given the pre-test sample quality assessment experiments and 2-3 repeat experiments, 0.2 ml of whole blood is adequate to perform the YiDiXie™ test[8]. The average patient can use a finger blood collection needle to collect 0.2 ml of finger blood at home, instead of requiring venous blood collection by medical personnel, making the diagnostic process non-invasive without having to leave the patient's home[8].

On the other hand, the YiDiXie™ test has a nearly unlimited diagnostic capacity. Figure 1 shows the basic flow chart of the YiDiXie™ test, which shows that the YiDiXie ™ test not only requires no doctors or medical equipment, but also requires no medical personnel to collect blood[8]. Therefore, the YiDiXie ™ test is completely independent of the number of medical personnel and medical facilities, and its testing capacity is nearly unlimited[8]. This allows the YiDiXie™ test to "just-in-time" diagnose brain tumors without the patient having to wait anxiously for an appointment.

In short, the YiDiXie™ test has an important diagnostic value in brain tumors, and it is expected to solve the problems of "high false-negative rate

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

of enhanced MRI" and "high false-positive rate of enhanced MRI" for brain tumors.



Figure 1. Basic flowchart of the YiDiXie™ test.

Limitations of the study

First, this study had a small number of cases and future clinical studies with larger sample sizes are needed for further evaluation.

Second, the present study was an inpatient malignant tumor case-benign tumor control study, and future cohort studies in the natural population of brain tumors are needed for further evaluation.

Final, the current study was a single-center study, which may have led to some degree of bias in the results of this study. Multicenter studies are needed to further evaluate this in the future.

CONCLUSION

YiDiXie ™ -SS significantly reduces the false-positive rate of brain-enhanced MRI without increasing the delay in treatment of malignant tumors. YiDiXie ™ -HS dramatically reduces the false-negative rate of brain-enhanced MRI. YiDiXie ™-D dramatically reduces the false-positive rate of brain-enhanced MRI. The YiDiXie ™ test has significant diagnostic value in brain tumors, and is expected to solve the problems of " high false-negative rate of enhancement MRI " and "high false-positive rate of enhancement MRI" in brain tumors.

FUNDING

This study was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.18.24311913; this version posted August 19, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

REFERENCES

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024.
2. Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-49.
3. Louis D N, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [J]. Neuro-Oncology, 2021, 23(8): 1231-51.
4. Schaff L R, Mellinghoff I K. Glioblastoma and Other Primary Brain Malignancies in Adults [J]. Jama, 2023, 329(7).
5. Roger Stupp M D, Warren P. Mason, M.D., Martin J. van den Bent, M.D., Michael Weller, M.D., Barbara Fisher, M.D., Martin J.B. Taphoorn, M.D., Karl Belanger, M.D., et al; for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma [J]. The new England journal of medicine, 2005.
6. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma [J]. Jama, 2017, 318(23).
7. Paula Sherwood B G, Charles Given, Rachel Schiffman, Daniel Murman, Mary Lovely. Caregivers of persons with a brain tumor: a conceptual model [J]. Nursing Inquiry 2004.
8. Chen Sun, Chong Lu, Yongjian Zhang, et al. Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie™-HS and YiDiXie™-SS [J]. medRxiv, 2024: doi: 10.1101/2024.03.11.24303683.
9. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474.
10. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017, 67(2):93-99.